Chronic traumatic encephalopathy (CTE) remains a postmortem diagnosis because its defining feature is a microscopic pattern of abnormal tau protein clustered around tiny blood vessels deep in the brain’s folds, and no scan, blood draw, or clinical exam performed on a living person can yet detect that pattern with enough reliability to confirm the disease. Researchers have identified the clinical syndrome associated with CTE and are chasing biomarkers that could change this, but the gap between what a neuropathologist can see on a glass slide and what any tool can reveal in a living brain is still wide.
The Microscopic Signature That Defines CTE
CTE is defined not by symptoms but by a specific arrangement of misfolded tau protein in the brain. The hallmark lesion is an accumulation of hyperphosphorylated tau in neurons and surrounding support cells (astrocytes), clustered around small blood vessels at the deepest points of the brain’s cortical grooves, called sulcal depths.1PubMed Central. The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy That pattern is irregular, patchy, and unlike anything seen in normal aging, Alzheimer’s disease, or other tau-related brain diseases.2PubMed Central. Chronic traumatic encephalopathy (CTE): criteria for neuropathological diagnosis and relationship to repetitive head impacts
This is the crux of the problem. The signature is visible only when thin slices of brain tissue are stained with antibodies that light up the abnormal tau and then examined under a microscope. A neuropathologist looks for that perivascular pattern in the sulcal depths, and when it is there, the diagnosis is CTE. When it is not, the diagnosis is not CTE, no matter what symptoms the person had while alive. No imaging technology currently in use can resolve structures at that scale in a living brain or distinguish CTE’s tau deposits from those of other diseases with similar protein buildups.
A Tau Shape Found Nowhere Else
One reason CTE’s pathology is so hard to catch with existing tools is that its tau filaments fold into a shape that is structurally distinct from the tau tangles of every other known brain disease. Using cryo-electron microscopy on tissue from deceased individuals with CTE, researchers determined that the tau filaments form a unique configuration with a hydrophobic cavity that is absent in Alzheimer’s disease tau.3Nature. Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules The filament structures were identical across three separate CTE cases but different from tau filaments in Alzheimer’s, Pick’s disease, and lab-grown tau. This uniqueness is actually good news in theory: it means CTE has a molecular fingerprint that could eventually be targeted by a diagnostic tool. In practice, though, we do not yet have a way to image or measure that specific fold in a living person’s brain.
Why Brain Scans Cannot See CTE
PET scans designed to detect tau in the brain have revolutionized Alzheimer’s research, but they have not done the same for CTE. Several tau-targeting radiotracers have been tested against confirmed CTE brain tissue, and the results are sobering. Flortaucipir, the most widely used tau tracer, did show a positive signal in all CTE cases examined, but a significant portion of that signal turned out to be off-target binding to an unrelated enzyme (monoamine oxidase A), not to CTE tau itself.4PubMed Central. Evaluation of Tau Radiotracers in Chronic Traumatic Encephalopathy Other tracers, including MK-6240 and PI-2620, showed almost no binding in CTE tissue except in the most severe cases, and even then the signal may have been driven by overlapping Alzheimer’s pathology rather than CTE itself.
The core issue is that current tau PET tracers were designed to bind Alzheimer’s-type tau tangles. CTE’s tau has a different fold, a different spatial distribution, and different surrounding molecular neighbors. A tracer that works beautifully in Alzheimer’s can be essentially blind to CTE. Developing a tracer that locks onto CTE-specific tau without also lighting up from unrelated molecules is an active area of research, but nothing clinically validated exists yet.
Structural MRI can pick up some changes associated with repetitive head impacts. In a series of patients who met clinical criteria for the syndrome associated with CTE, medial temporal lobe atrophy and poor white matter integrity in the fornix were consistently observed.5PubMed Central. Multi-Modal Biomarkers of Repetitive Head Impacts and Traumatic Encephalopathy Syndrome: A Clinicopathological Case Series But brain shrinkage and white matter damage show up in many neurodegenerative conditions. These MRI findings can support a clinical suspicion of CTE-related decline, but they cannot distinguish CTE from Alzheimer’s, frontotemporal dementia, or even depression-related brain changes on their own.
Blood Tests Show Promise but Not Proof
If brain scans cannot see CTE, maybe something in the blood can hint at it. Researchers have explored several plasma biomarkers in people with histories of repetitive head impacts, and some patterns are emerging. Former professional football players showed higher levels of certain phosphorylated tau markers (p-tau181 and p-tau231) compared to controls, along with elevated markers of brain cell damage and inflammation. However, the ability of p-tau alone to distinguish former players from controls was modest.6Wiley Online Library (Alzheimer’s & Dementia). Examination of plasma biomarkers of amyloid, tau, neurodegeneration, and neuroinflammation in former elite American football players “Modest” means that while the signal is there on a group level, an individual blood draw cannot tell you with confidence whether a given person has CTE pathology in their brain.
A separate approach has looked at tau carried inside tiny vesicles shed by neurons into the bloodstream, called exosomes. In a preliminary study, former NFL players had significantly higher exosomal tau than controls, and the test identified players with high sensitivity and perfect specificity in that sample.7PubMed Central. Preliminary Study of Plasma Exosomal Tau as a Potential Biomarker for Chronic Traumatic Encephalopathy Higher exosomal tau also correlated with worse performance on memory and processing-speed tests. These are encouraging numbers, but the study was small, and the participants were not matched against people with confirmed CTE pathology at autopsy. Finding elevated tau in someone’s blood after years of contact sports is not the same as confirming CTE in their brain.
The broader challenge with blood biomarkers is specificity. Phosphorylated tau rises in Alzheimer’s disease. Neurofilament light chain (NfL), another commonly measured marker, goes up after almost any kind of brain injury or neurodegeneration. GFAP, a marker of astroglial activity, increases in multiple conditions. None of these markers is unique to CTE, so while a combination panel might one day help flag people at high risk, it is unlikely that any single blood test will serve as a definitive CTE diagnosis in the foreseeable future.
Traumatic Encephalopathy Syndrome as the Clinical Stand-In
Because CTE itself cannot be diagnosed in a living person, researchers have developed a clinical framework to identify people who are likely experiencing the effects of CTE-related brain changes. This framework is called Traumatic Encephalopathy Syndrome (TES). In 2021, the National Institute of Neurological Disorders and Stroke published consensus diagnostic criteria for TES, designed to be used in research settings.8PubMed Central. National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome
TES is not CTE. It is a clinical diagnosis based on a history of substantial repetitive head impacts combined with progressive cognitive, behavioral, or mood symptoms that cannot be fully explained by another condition. Think of it as the living-person version of saying “this person’s brain is probably accumulating CTE pathology.” A TES diagnosis can be rated as “suggestive of CTE,” “possible CTE,” or “probable CTE,” but none of these labels is a confirmed diagnosis. The only way to move from “probable” to “definite” is still autopsy.
This distinction matters clinically. A person diagnosed with TES can receive treatment for their symptoms, including cognitive rehabilitation, psychiatric medications, and lifestyle support. But they and their doctors are working without certainty about what is happening at the tissue level. That uncertainty affects everything from prognosis to treatment planning to legal considerations.
The Overlap Problem With Other Diseases
CTE’s symptoms during life are maddeningly nonspecific. Memory loss, impulsivity, depression, aggression, poor executive function, difficulty with planning: these appear in Alzheimer’s disease, frontotemporal dementia, major depressive disorder, post-traumatic stress disorder, and substance use disorders. Many people with repetitive head impact exposure have more than one of these conditions simultaneously. At autopsy, researchers frequently find CTE pathology alongside Alzheimer’s pathology or other age-related changes, making it hard to untangle which disease was driving which symptoms.
The disease also progresses through stages, classified from stage I (mild, focal tau deposits) through stage IV (severe, widespread tau throughout the brain).9PubMed Central. Characterizing tau deposition in chronic traumatic encephalopathy (CTE): utility of the McKee CTE staging scheme Early-stage CTE can be clinically silent or produce symptoms so mild they get attributed to normal aging, stress, or mood disorders. By the time symptoms become severe enough to prompt medical workup, other neurodegenerative processes may have started as well, making clinical distinction from CTE essentially impossible without tissue confirmation.
There is also a less well-known confound: aging-related tau astrogliopathy, or ARTAG, which deposits tau in astrocytes in patterns that can overlap with early CTE changes. ARTAG is extremely common in aging brains and has been proposed as a possible precursor to or co-occurring feature of CTE. Even trained neuropathologists sometimes debate borderline cases, which underscores how subtle the distinction between CTE pathology and normal aging-related tau can be.
Genetics Add Another Layer of Complexity
Not everyone who sustains repetitive head impacts develops CTE, and genetic variation appears to play a role in who is most vulnerable. The APOE ε4 gene variant, already well known as a risk factor for Alzheimer’s disease, has been linked to CTE severity. Among brain donors older than 65 who had confirmed CTE at autopsy, carrying the ε4 variant more than doubled the odds of having a higher CTE stage and was associated with substantially greater tau buildup in the frontal lobe.10PubMed Central. Association of APOE Genotypes and Chronic Traumatic Encephalopathy
The tau gene itself (MAPT) also appears to matter. A preprint study of retired professional fighters found that one MAPT variant seemed to offer partial protection against brain-cell damage and hippocampal shrinkage from head-impact exposure, while another variant was enriched among fighters meeting TES criteria.11medRxiv. APOE4 genotype and MAPT haplotype modify repetitive head impact biomarkers in retired professional fighters These genetic modifiers matter for diagnosis because they mean two people with identical head-impact histories can have very different trajectories, making it harder to predict who has CTE pathology based on exposure history and symptoms alone. They also raise the possibility that genetic profiling could eventually help stratify risk, even if it cannot confirm a diagnosis.
Selection Bias and What It Obscures
Almost everything we know about CTE comes from brain banks, and brain banks have a built-in problem: the brains that get donated are not a random sample. Families who donate a loved one’s brain tend to do so because the person had noticeable symptoms during life, which creates a skew toward more severe cases. A recent population-level study of deceased NFL players found that those who donated their brains to research had played professionally for longer, appeared in more all-star games, and were more commonly Hall of Fame inductees compared to non-donors.12PubMed. Prevalence of chronic traumatic encephalopathy at death in National Football League players: retrospective population based cohort study, 2008-21 Longer careers mean more cumulative head impacts, and more impacts likely mean more symptoms motivating donation.
This selection pressure matters for diagnosis because it distorts our understanding of how common CTE is and how reliably symptoms predict pathology. If the people whose brains we study are disproportionately those with the most exposure and the worst symptoms, we may be overestimating how tightly symptoms track with the disease. A diagnostic tool calibrated on brain-bank data could perform differently when applied to the broader population of people who played contact sports, many of whom never develop significant symptoms. Epidemiological analyses have pointed out that this kind of selection bias needs to be accounted for before any generalizable estimate of the link between head impacts and CTE can be established.13PubMed Central. Relationship Between Level of American Football Playing and Diagnosis of Chronic Traumatic Encephalopathy in a Selection Bias Analysis
Technologies That Could Eventually Break the Barrier
The most intriguing lead for in-life CTE detection may come from a class of lab tests called seed amplification assays. These work by taking a tiny amount of misfolded protein from a patient’s spinal fluid and using it as a template to grow more of the same misfolded shape in a test tube, amplifying the signal until it becomes detectable. A version of this approach has already been developed for a different group of tau diseases (4-repeat tauopathies like progressive supranuclear palsy and corticobasal degeneration). In that work, the assay detected tau seeds in cerebrospinal fluid from all confirmed cases while producing no signal in controls, and it was far less responsive to Alzheimer’s-type tau.14PubMed Central. 4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration
CTE’s tau has a unique filament structure, which in principle means an assay could be tuned to amplify specifically CTE-type seeds and ignore Alzheimer’s-type or aging-related tau. Developing that assay and validating it against confirmed CTE cases is exactly the kind of work the field is pursuing. But validation requires large numbers of people who have both spinal fluid collected during life and confirmed pathology at autopsy, and building that kind of longitudinal dataset takes years. A 2025 expert summit emphasized that coordinated, long-term studies linking clinical data to autopsy findings are the critical bottleneck for advancing any CTE biomarker from promising laboratory finding to clinically useful test.15Wiley Online Library (Alzheimer’s & Dementia). Advancing biomarker development for chronic traumatic encephalopathy: Summary and recommendations from the 2025 Leon Thal Summit
Research into the mechanism connecting head impacts to tau buildup may also open diagnostic doors. Computational and lab studies have shown that the regions of the brain where CTE tau deposits first appear correspond to areas that experience the most physical deformation during an impact, and that the mechanical energy of high-strain-rate deformation alone can trigger tau to move to abnormal locations in neurons and become hyperphosphorylated.16PubMed Central. Mechanical injuries of neurons induce tau mislocalization to dendritic spines and tau-dependent synaptic dysfunction This kind of mechanistic understanding could eventually inform which brain regions to scan with more targeted tracers, or which early cellular changes to look for in fluid biomarkers, though these applications are still years from clinical use.
When People Started Getting Hit and Why It Matters
One factor that does appear to influence the clinical picture is how early in life repetitive head impacts began. Among people with confirmed CTE at autopsy, every year younger a person was when they started playing tackle football predicted earlier onset of cognitive symptoms by about two and a half years. Starting before age 12 was associated with cognitive and behavioral symptoms appearing roughly 13 years earlier than in those who started later.17PubMed Central. Age of First Exposure to Tackle Football and Chronic Traumatic Encephalopathy
This finding does not help diagnose CTE in a living person, but it has significant implications for how the disease is understood and studied. If earlier exposure accelerates symptom onset, then people who began contact sports as young children may present with cognitive and mood problems at ages when clinicians are not expecting neurodegeneration. A 45-year-old former football player with memory complaints and behavioral changes might be evaluated for depression or early-onset Alzheimer’s before anyone considers CTE-related pathology, especially if no validated diagnostic test exists. The age-of-exposure data also reinforces that prevention through limiting youth contact-sport participation may be the most actionable tool available while diagnosis remains locked behind the autopsy barrier.
Proteins carried by neuron-derived exosomes in the blood may also be relevant here. Research has suggested that certain exosome-associated proteins can bind and concentrate toxic forms of tau and amyloid-beta for delivery to other neurons, potentially spreading damage from the original injury site to distant brain regions.18Frontiers in Neuroscience. Neuron-Derived Exosome Proteins May Contribute to Progression From Repetitive Mild Traumatic Brain Injuries to Chronic Traumatic Encephalopathy If this spreading mechanism can be detected in blood exosomes early in the disease course, it could provide a window into the progression of CTE-like changes years before severe symptoms appear. That is a long “if,” but it represents one more thread that researchers are pulling on as they try to bring CTE diagnosis into the realm of the living.